|
1
|
Senkomago V, Duran D, Loharikar A, Hyde
TB, Markowitz LE, Unger ER and Saraiya M: CDC activities for
improving implementation of human papillomavirus vaccination,
cervical cancer screening, and surveillance worldwide. Emerg Infect
Dis. 23:2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fader AN: Surgery in cervical cancer. N
Engl J Med. 379:1955–1957. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiang X, Tang H and Chen T: Epidemiology
of gynecologic cancers in China. J Gynecol Oncol. 29:e72018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsu V and Jeronimo J: Saving the World's
Women from Cervical Cancer. The New England J Med. 374:2509–2511.
2016. View Article : Google Scholar
|
|
5
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schlecht NF, Kulaga S, Robitaille J,
Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE,
Ferenczy A, Villa LL and Franco EL: Persistent human papillomavirus
infection as a predictor of cervical intraepithelial neoplasia.
JAMA. 286:3106–3114. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saraiya M, Unger ER, Thompson TD, Lynch
CF, Hernandez BY, Lyu CW, Steinau M, Watson M, Wilkinson EJ,
Hopenhayn C, et al: US assessment of HPV types in cancers:
Implications for current and 9-valent HPV vaccines. J Natl Cancer
Inst. 107:djv0862015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kahn JA: HPV vaccination for the
prevention of cervical intraepithelial neoplasia. N Engl J Med.
361:271–278. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baumeister SH, Freeman GJ, Dranoff G and
Sharpe AH: Coinhibitory pathways in immunotherapy for cancer. Annu
Rev Immunol. 34:539–573. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Topalian SL, Taube JM, Anders RA and
Pardoll DM: Mechanism-driven biomarkers to guide immune checkpoint
blockade in cancer therapy. Nat Rev Cancer. 16:275–287. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu F, Liu Y and Chen Z: Tim-3 expression
and its role in hepatocellular carcinoma. J Hematol Oncol.
11:1262018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
de Mingo Pulido A, Gardner A, Hiebler S,
Soliman H, Rugo HS, Krummel MF, Coussens LM and Ruffell B: TIM-3
regulates CD103(+) dendritic cell function and response to
chemotherapy in breast cancer. Cancer Cell. 33:60–74.e6. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He Y, Cao J, Zhao C, Li X, Zhou C and
Hirsch FR: TIM-3, a promising target for cancer immunotherapy. Onco
Targets Ther. 11:7005–7009. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li X, Hu W, Zheng X, Zhang C, Du P, Zheng
Z, Yang Y, Wu J, Ji M, Jiang J and Wu C: Emerging immune
checkpoints for cancer therapy. Acta Oncol. 54:1706–1713. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moriyama K, Kukita A, Li YJ, Uehara N,
Zhang JQ, Takahashi I and Kukita T: Regulation of
osteoclastogenesis through Tim-3: Possible involvement of the
Tim-3/galectin-9 system in the modulation of inflammatory bone
destruction. Lab Invest. 94:1200–1211. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chou FC, Kuo CC, Chen HY, Chen HH and
Sytwu HK: DNA demethylation of the TIM-3 promoter is critical for
its stable expression on T cells. Genes Immun. 17:179–186. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sasidharan Nair V, El Salhat H, Taha RZ,
John A, Ali BR and Elkord E: DNA methylation and repressive H3K9
and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4,
TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast
cancer. Clin Epigenetics. 10:782018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao Y, Zhou X, Huang X, Li Q, Gao L, Jiang
L, Huang M and Zhou J: Tim-3 expression in cervical cancer promotes
tumor metastasis. PLoS One. 8:e538342013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liang M, Ueno M, Oomizu S, Arikawa T,
Shinonaga R, Zhang S, Yamauchi A and Hirashima M: Galectin-9
expression links to malignant potential of cervical squamous cell
carcinoma. J Cancer Res Clin Oncol. 134:899–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Azizmohammadi S, Azizmohammadi S, Safari
A, Kaghazian M, Sadrkhanlo M, Behnod V and Seifoleslami M:
High-level expression of RIPK4 and EZH2 contributes to lymph node
metastasis and predicts favorable prognosis in patients with
cervical cancer. Oncol Res. 25:495–501. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun J, Ji J, Huo G, Song Q and Zhang X:
miR-182 induces cervical cancer cell apoptosis through inhibiting
the expression of DNMT3a. Int J Clin Exp Pathol. 8:4755–4763.
2015.PubMed/NCBI
|
|
22
|
Cao D, Zhang S, Zhang Q, Wei X, Zhao M, Ma
Q, Li Y, Wang L, Pei M, Yang T, et al: Prevalence of high-risk
human papillomavirus infection among women in Shaanxi province of
China: A hospital-based investigation. J Med Virol. 89:1281–1286.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wei X, Zhang S, Cao D, Zhao M, Zhang Q,
Zhao J, Yang T, Pei M, Wang L, Li Y and Yang X: Aberrant
hypermethylation of SALL3 with HPV involvement contributes to the
carcinogenesis of cervical cancer. PLoS One. 10:e01457002015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao M, Li Y, Wei X, Zhang Q, Jia H, Quan
S, Cao D, Wang L, Yang T, Zhao J, et al: Negative immune factors
might predominate local tumor immune status and promote
carcinogenesis in cervical carcinoma. Virol J. 14:52017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Simon JA and Lange CA: Roles of the EZH2
histone methyltransferase in cancer epigenetics. Mutat Res.
647:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu Y, Chen J, Pang B, Li C, Zhao J and
Shen K: EZH2-induced H3K27me3 is associated with epigenetic
repression of the ARHI tumor-suppressor gene in ovarian cancer.
Cell Biochem Biophys. 71:105–112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ler LD, Ghosh S, Chai X, Thike AA, Heng
HL, Siew EY, Dey S, Koh LK, Lim JQ, Lim WK, et al: Loss of tumor
suppressor KDM6A amplifies PRC2-regulated transcriptional
repression in bladder cancer and can be targeted through inhibition
of EZH2. Sci Transl Med. 9:eaai83122017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen PM, Cheng YW, Wang YC, Wu TC, Chen CY
and Lee H: Up-regulation of FOXM1 by E6 oncoprotein through the
MZF1/NKX2-1 axis is required for human papillomavirus- associated
tumorigenesis. Neoplasia. 16:961–971. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Urrego D, Movsisyan N, Ufartes R and Pardo
LA: Periodic expression of Kv10.1 driven by pRb/E2F1 contributes to
G2/M progression of cancer and non-transformed cells. Cell Cycle.
15:799–811. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Finzer P, Krueger A, Stohr M, Brenner D,
Soto U, Kuntzen C, Krammer PH and Rösl F: HDAC inhibitors trigger
apoptosis in HPV-positive cells by inducing the E2F-p73 pathway.
Oncogene. 23:4807–4817. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McCance DJ: Human papillomaviruses and
cell signaling. Science's STKE. 2005:pe292005.
|
|
33
|
Ghosh K, Chatterjee B, Maheswari U, Athifa
M and Kanade SR: 4-Nonylphenol-enhanced EZH2 and RNF2 expression,
H3K27me3 and H2AK119ub1 marks resulting in silencing of p21(CDKN1A)
in vitro. Epigenomics. 11:899–916. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Y, Wu M, Lei Z, Huang M, Li Z, Wang
L, Wang L, Cao Q, Han D, Chang Y, et al: Dysregulation of
miR-6868-5p/FOXM1 circuit contributes to colorectal cancer
angiogenesis. J Exp Clin Cancer Res. 37:2922018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mersakova S, Nachajova M, Szepe P,
Kasajova PS and Halasova E: DNA methylation and detection of
cervical cancer and precancerous lesions using molecular methods.
Tumor Biol. 37:23–27. 2016. View Article : Google Scholar
|
|
36
|
Steenbergen RD, Snijders PJ, Heideman DA
and Meijer CJ: Clinical implications of (epi)genetic changes in
HPV-induced cervical precancerous lesions. Nat Rev Cancer.
14:395–405. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cicchini L, Blumhagen RZ, Westrich JA,
Myers ME, Warren CJ, Siska C, Raben D, Kechris KJ and Pyeon D:
High-risk human papillomavirus E7 alters Host DNA methylome and
represses HLA-E expression in human keratinocytes. Sci Rep.
7:36332017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yasmin R, Siraj S, Hassan A, Khan AR,
Abbasi R and Ahmad N: Epigenetic regulation of inflammatory
cytokines and associated genes in human malignancies. Mediators
Inflamm. 2015:2017032015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Micevic G, Thakral D, McGeary M and
Bosenberg MW: PD-L1 methylation regulates PD-L1 expression and is
associated with melanoma survival. Pigment Cell Melanoma Res.
32:435–440. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang T, Wu J, Ungvijanpunya N,
Jackson-Weaver O, Gou Y, Feng J, Ho TV, Shen Y, Liu J, Richard S,
et al: Smad6 Methylation Represses NFκB activation and periodontal
inflammation. J Dent Res. 97:810–819. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang Y, Zhao E, Zhang Z, Zhao G and Cao H:
Association between Tim3 and Gal9 expression and gastric cancer
prognosis. Oncol Rep. 40:2115–2126. 2018.PubMed/NCBI
|
|
42
|
Hou N, Ma J, Li W, Zhao L, Gao Q and Mai
L: T-cell immunoglobulin and mucin domain-containing protein-3 and
galectin-9 protein expression: Potential prognostic significance in
esophageal squamous cell carcinoma for Chinese patients. Oncol
Lett. 14:8007–8013. 2017.PubMed/NCBI
|
|
43
|
Komohara Y, Morita T, Annan DA, Horlad H,
Ohnishi K, Yamada S, Nakayama T, Kitada S, Suzu S, Kinoshita I, et
al: The Coordinated Actions of TIM-3 on cancer and myeloid cells in
the regulation of tumorigenicity and clinical prognosis in clear
cell renal cell carcinomas. Cancer Immunol Res. 3:999–1007. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liang T, Wang X, Wang F, Feng E and You G:
Galectin-9: A predictive biomarker negatively regulating immune
response in glioma patients. World Neurosurg. Aug 27–2019.(Epub
ahead of print). doi: 10.1016/j.wneu.2019.08.117. View Article : Google Scholar
|
|
45
|
Zhou T, Sun Y, Li M, Ding Y, Yin R, Li Z,
Xie Q, Bao S and Cai W: Enhancer of zeste homolog 2-catalysed H3K27
trimethylation plays a key role in acute-on-chronic liver failure
via TNF-mediated pathway. Cell Death Dis. 9:5902018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sharma V, Malgulwar PB, Purkait S, Patil
V, Pathak P, Agrawal R, Kulshreshtha R, Mallick S, Julka PK, Suri
A, et al: Genome-wide ChIP-seq analysis of EZH2-mediated H3K27me3
target gene profile highlights differences between low- and
high-grade astrocytic tumors. Carcinogenesis. 38:152–161.
2017.PubMed/NCBI
|
|
47
|
Cui H, Hu Y, Guo D, Zhang A, Gu Y, Zhang
S, Zhao C, Gong P, Shen X, Li Y, et al: DNA methyltransferase 3A
isoform b contributes to repressing E-cadherin through cooperation
of DNA methylation and H3K27/H3K9 methylation in EMT-related
metastasis of gastric cancer. Oncogene. 37:4358–4371. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mochizuki D, Misawa Y, Kawasaki H, Imai A,
Endo S, Mima M, Yamada S, Nakagawa T, Kanazawa T and Misawa K:
Aberrant epigenetic regulation in head and neck cancer due to
distinct EZH2 overexpression and DNA hypermethylation. Int J Mol
Sci. 19:E37072018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Manzo M, Wirz J, Ambrosi C, Villasenor R,
Roschitzki B and Baubec T: Isoform-specific localization of DNMT3A
regulates DNA methylation fidelity at bivalent CpG islands. EMBO J.
36:3421–3434. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hyland PL, Mcdade SS, Mccloskey R, Dickson
GJ, Arthur K, McCance DJ and Patel D: Evidence for alteration of
EZH2, BMI1, and KDM6A and epigenetic reprogramming in human
papillomavirus type 16 E6/E7-expressing keratinocytes. J Virol.
85:10999–11006. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lindsay CD, Kostiuk MA, Harris J,
O'Connell DA, Seikaly H and Biron VL: Efficacy of EZH2 inhibitory
drugs in human papillomavirus-positive and human
papillomavirus-negative oropharyngeal squamous cell carcinomas.
Clin Epigenetics. 9:952017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Biron VL, Mohamed A, Hendzel MJ, Alan
Underhill D and Seikaly H: Epigenetic differences between human
papillomavirus-positive and -negative oropharyngeal squamous cell
carcinomas. J Otolaryngol Head Neck Surg. 41 (Suppl 1):S65–S70.
2012.PubMed/NCBI
|
|
53
|
Leonard S, Pereira M, Fox R, Gordon N, Yap
J, Kehoe S, Luesley D, Woodman C and Ganesan R: Over-expression of
DNMT3A predicts the risk of recurrent vulvar squamous cell
carcinomas. Gynecol Oncol. 143:414–420. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Liu X, Li C, Zhang R, Xiao W, Niu X, Ye X,
Li Z, Guo Y, Tan J and Li Y: The EZH2- H3K27me3-DNMT1 complex
orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP
pathway upstream effector, in breast cancer epithelial cells. Cell
Signal. 51:243–256. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hladikova K, Partlova S, Koucky V, Boucek
J, Fonteneau JF, Zabrodsky M, Tachezy R, Grega M, Špíšek R and
Fialová A: Dysfunction of HPV16-specific CD8+ T cells
derived from oropharyngeal tumors is related to the expression of
Tim-3 but not PD-1. Oral Oncol. 82:75–82. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Holland D, Hoppe-Seyler K, Schuller B,
Lohrey C, Maroldt J, Dürst M and Hoppe-Seyler F: Activation of the
enhancer of zeste homologue 2 gene by the human papillomavirus E7
oncoprotein. Cancer Res. 68:9964–9972. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yeo-Teh NSL, Ito Y and Jha S: High-risk
human papillomaviral oncogenes E6 and E7 target key cellular
pathways to achieve oncogenesis. Int J Mol Sci. 19:E17062018.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Vuillier C, Lohard S, Fetiveau A, Allegre
J, Kayaci C, King LE, Braun F, Barillé-Nion S, Gautier F, Dubrez L,
et al: E2F1 interacts with BCL-xL and regulates its subcellular
localization dynamics to trigger cell death. EMBO Rep. 19:234–243.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Youn HS, Kim TY, Park UH, Moon ST, An SJ,
Lee YK, Hwang JT, Kim EJ and Um SJ: Asxl1 deficiency in embryonic
fibroblasts leads to cellular senescence via impairment of the
AKT-E2F pathway and Ezh2 inactivation. Sci Rep. 7:51982017.
View Article : Google Scholar : PubMed/NCBI
|
